Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma

References

• Goel M, Picciani RG, Lee RK, et al. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010;4:52–59.
   PubMedGoogle Scholar
• Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol. 2000;11:112–115.
   PubMedGoogle Scholar
• Klimko PG, Sharif NA. Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma. Br J Pharmacol. 2018;17. Apr. Review. doi: 10.1111/bph.14327
   Google Scholar
• Winkler N, Fautsch MP. Prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther Mar-Apr 30(2–3):102–109.
   PubMed Web of Science ®Google Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17:667–673.
   PubMed Web of Science ®Google Scholar
• Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53(Suppl1):S107–S120. Review.
   PubMed Web of Science ®Google Scholar
• Krauss AH, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol. 2004 Mar;49(Suppl 1):S5–S11. Review.
   PubMed Web of Science ®Google Scholar
• Musch DC, Lichter PR, Guire KE, et al. The collaborative initial glaucoma treatment study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106:653–662.
   PubMed Web of Science ®Google Scholar
• Ederer F, Gaasterland DE, Sullivan EK, et al. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials. 1994;15:299–325.
   PubMedGoogle Scholar
• Singh K, Shrivastava A. Medical management of glaucoma: principles and practice. Indian J Ophthalmol. 2011;59(suppl1):S88–S92.
   PubMed Web of Science ®Google Scholar
• Sakurai M, Higashide T, Ohkubo S, et al. Association between genetic polymorphisms of the prostaglandin F2α receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension. Br J Ophthalmol. 2014 Apr;98(4):469–473.
   PubMed Web of Science ®Google Scholar
• Scherer WJ. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther. 2002;18:287–291.
   PubMed Web of Science ®Google Scholar
• Ganesh T. Prostanoid receptor EP2 as a therapeutic target. J Med Chem. 2014 Jun 12;57(11):4454–4465. Epub 2013 Dec 4.
   PubMed Web of Science ®Google Scholar
• Alexander SPH, Christopoulos A, Davenport AP, et al. The concise guide to pharmacology 2017/18: G protein-coupled receptors. Br J Pharmacol. 2017;174:S17–S129.
   PubMed Web of Science ®Google Scholar
• Woodward DF, Regan JW, Lake S, et al. The molecular biology and ocular distribution of prostanoid receptors. Surv Ophthalmol. 1997 Feb;41(Suppl 2):S15–S21.
   PubMedGoogle Scholar
• Millard LH, Woodward DF, Stamer WD. The role of the prostaglandin EP4 receptor in the regulation of human outflow facility. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3506–3513.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Bian L, Yin H, et al. Localization of EP(1) and FP receptors in human ocular tissues by in situ hybridization. Invest Ophthalmol Vis Sci. 2001 Feb;42(2):424–428.
   PubMed Web of Science ®Google Scholar
• Schlötzer Schrehardt U, Zenkel M, Nüsing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002 May;43(5):1475–1487.
   PubMed Web of Science ®Google Scholar
• Anthony TL, Pierce KL, Stamer WD, et al. Prostaglandin F2 receptors in the human trabecular meshwork. Invest Ophthalmol Vis Sci. 1998;39:315–321.
   PubMed Web of Science ®Google Scholar
• Doucette LP, Ma W. Prostaglandins in the eye: function, expression, and roles in glaucoma. Ophthalmic Genet 2017 Mar-Apr 38(2):108–116. Epub 2016 Apr 12. Review.
   PubMed Web of Science ®Google Scholar
• Noecker RS, Dirks MS, Choplin NT, et al.; for the Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55–63.
   PubMed Web of Science ®Google Scholar
• Wand M, Ritch R, Isbey EK, et al. Latanoprost and periocular skin changes. Arch Ophthalmol. 2001;119(4):614–615.
   PubMedGoogle Scholar
• Horsley MB, Chen TC. The use of prostaglandin analogs in the uveitic patient. Semin Ophthalmol. 2011 Jul-Sep;26(4–5):285–289.
   PubMed Web of Science ®Google Scholar
• Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002 Aug;47(Suppl 1):S203–S218.
   PubMed Web of Science ®Google Scholar
• Vegge T, Neufeld AH, Sears ML. Morphology of the breakdown of the blood-aqueous barrier in the ciliary processes of the rabbit eye after prostaglandin E2. Invest Ophthalmol. 1975 Jan;14(1):33–36.
   PubMedGoogle Scholar
• Nilsson SFE, Drecoll E, Lütjen-Drecoll E, et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci. 2006;47:4042–4049.
   PubMed Web of Science ®Google Scholar
• Kamphuis W, Schneemann A, van Beek LM, et al. Prostanoid receptor gene expression profile in human trabecular meshwork: a quantitative real-time PCR approach. Invest Ophthalmol Vis Sci. 2001;42:3209–3215.
   PubMed Web of Science ®Google Scholar
• Kirihara T, Iwamura R, Yoneda K, et al. (2015). DE-117, a selective EP2 agonist, lowered intraocular pressure in animal models. IOVS 56: ARVO E-abstract 5709.
   Google Scholar
• Ihekoromadu N, Lu F, Iwamura R, et al. Safety and Efficacy of DE-117, a Selective EP2 Agonist in a Phase 2a Study. Association for Research in Vision and Ophthalmology. Invest Ophthalmol Vis. E-Abstract5708. 2015 [Accessed 2018 Jun 29];56. Available at https://iovs.arvojournals.org/article.aspx?articleid=2335/769&resultClick=1
   Web of Science ®Google Scholar
• Kirihara T, Taniguchi T, Yamamura K, et al. Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent. Invest Ophthalmol Vis Sci. 2018;59:145–153.
   PubMed Web of Science ®Google Scholar
• Fuwa M, Toris CB, Fan S, et al. Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. J Ocul Pharmacol Ther. 2018 Jul 10.
   PubMedGoogle Scholar
• Iwamura R, Tanaka M, Okanari E, et al. Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: omidenepag and its Prodrug Omidenepag Isopropyl. J Med Chem. 2018 Jul 11.
   PubMed Web of Science ®Google Scholar
• Lu F, Aihara M, Kawata H, et al. A Phase 3 trial comparing omidenepag isopropyl 0.002% with latanoprost 0.005% in primary open-angle glaucoma and ocular hypertension: the AYAME study. ARVO 2018. E-abstract 31235 - A0076.
   Google Scholar
• Aihara M, Lu F, Kawata H, et al. Six-month efficacy and safety outcomes of a novel selective EP2 agonist omidenepag isopropyl: the RENGE study (Phase 3). ARVO 2018. E-abstract 31229 - A0070.
   Google Scholar
• Ropo AM, Aihara M, Lu F, et al. IOP lowering effect ofomidenepag isopropyl in latanoprost non-/low-responder subjects with primary openangle glaucoma or ocular hypertension: the FUJI study. ARVO 2018. E-abstract 31233 - A0074.
   Google Scholar
• Research & development – Santen. [cited 2018 July 24]. Available from: www.santen.com/en/rd/pdf/pipeline.pdf
   Google Scholar
• Prasanna G, Carreiro S, Anderson S, et al. Effect of PF-04217329 a prodrug of a selective prostaglandin EP2 agonist on intraocular pressure in preclinical models of glaucoma. Exp Eye Res. 2011;93:256–264.
   PubMed Web of Science ®Google Scholar
• Schachar RA, Raber S, Courtney R, et al. A Phase 2, randomized, dose-response trial of Taprenepag Isopropyl (PF-04217328) versus Latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr. Eye Res. 2011;36:809–817.
   PubMed Web of Science ®Google Scholar
• Yanochko GM, Affolter T, Eighmy JJ, et al. Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma. J Ocul Pharmacol Ther. 2014 Jun;30(5):429–439.
   PubMed Web of Science ®Google Scholar
• Liang Y, Li C, Guzman VM, et al. Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem. 2003 Jul 18;278(29):27267–27277. Epub 2003 Apr 30.
   PubMed Web of Science ®Google Scholar
• Markovič T, Jakopin Ž, Dolenc MS, et al. Structural features of subtype- selective EP receptor modulators. Drug Discov Today. 2017 Jan;22(1):57–71. Epub 2016 Aug 6.
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of AGN 210669 ophthalmic solution in patients with ocular hypertension or primary open-angle glaucoma. [cited 2018 July 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT00809848
   Google Scholar
• Safety and efficacy of AGN 210961 ophthalmic solution compared with bimatoprost ophthalmic solution in patients with glaucoma ocular hypertension. [cited 2018 July 25]. Available from: http://clinicaltrials.gov/ct2/show/NCT01110499
   Google Scholar
• Yamane S, Karakawa T, Nakayama S, et al. IOP-lowering effect of ONO-9054 –a novel dual agonist of prostanoid EP3 and FP receptors – in monkeys. Invest Ophthalmol Vis Sci. 2015;56:2547–2552.
   PubMed Web of Science ®Google Scholar
• Suto F, Rowe-Rendleman CL, Ouchi T, et al. Agonist of EP3 and FP Receptors for OAG and OHT: safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers. Invest Ophthalmol Vis Sci. 2015 Dec;56(13):7963–7970.
   PubMed Web of Science ®Google Scholar
• Harris A, Ward CL, Rowe- Rendleman CL, et al. Ocular hypotensive effect of ONO-9054, an EP3/FP receptor agonist: results of a randomized, placebo-controlled, dose escalation study. J Glaucoma. 2016 Oct;25(10):e826-e833.
   Web of Science ®Google Scholar
• Ellis EM, Berlin MS, Ward CL, et al. Ocular hypotensive effects and tolerability of the novel dual EP3/FP receptor agonist ONO-9054 vs. Xalatan: results of a 28 day, double masked, randomized study. Br J Opthalmol. 2017;101:796–800.
   PubMedGoogle Scholar
• A Phase IIb safety and efficacy study of DE-126 ophthalmic solution in primary open-angle glaucoma or ocular hypertension Angel study. [cited 2018 July 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03216902
   Google Scholar
• Prasanna G, Fortner J, Xiang C, et al. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models. Exp. Eye Res. 2009 Nov;89(5):608–617. Epub 2009 May 13.
   PubMed Web of Science ®Google Scholar
• Woodward DF, Nilsson SF, Toris CB, et al. Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow. Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3320–3328.
   PubMed Web of Science ®Google Scholar
• Millard LH, Woodward DF, Stamer WD. The role of the prostaglandin EP4 receptor in the regulation of human outflow facility. Invest Ophthalmol Vis Sci. 2011;52(6):3506–3513.
   PubMed Web of Science ®Google Scholar
• Krauss AH, Impagnatiello F, Toris CB, et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250–255.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Latanoprostene Bunod Ophthalmic Solution 0.024%: a review in open-angle glaucoma and ocular hypertension. Drugs. 2018 May;78(7):773–780.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738–745.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Scassellati Sforzolini B, Vittitow J, et al. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965–973.
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Martin KR, Peace J, et al. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angleglaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250–259.
   PubMed Web of Science ®Google Scholar
• Liu JH, Slight JR, Vittitow JL, et al. Efficacy of latanoprostene bunod 0.024% compared with timolol 0.5% in lowering intraocular pressure over 24 hours. Am J Ophthalmol. 2016;169:249–257.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Katsanos A, Russo A, et al. 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Surv Ophthalmol. 2013 Jan-Feb;58(1):26–41.
   PubMed Web of Science ®Google Scholar
• Kawase K, Vittitow JL, Weinreb RN, et al. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33(9):1612–1627.
   PubMed Web of Science ®Google Scholar
• Herreras JM, Pastor JC, Calonge M, et al. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992;99:1082–1088.
   PubMed Web of Science ®Google Scholar
• Wilson WS, Duncan AJ, Jay JL. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J Ophthalmol. 1975;59:667–669.
   PubMed Web of Science ®Google Scholar
• Daull P, Buggage R, Lambert G, et al. Study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK preserved latanoprost solution in animal models. J Ocul Pharmacol Ther. 2012;28(5):515–523.
   PubMed Web of Science ®Google Scholar
• Liang H, Baudouin C, Daull P, et al. In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models. Cornea. 2012 Nov;31(11):1319–1329.
   PubMed Web of Science ®Google Scholar
• Ismail D, Amrane M, Garrigue JS, et al. A phase 2, randomized study evaluating the safety and efficacy of Catioprost® (unpreserved latanoprost 0.005% emulsion) compared to Travatan Z® in subjects with glaucoma and ocular surface disease. Acta Ophthalmologica. 2011 September;89(248): Special Issue: Abstracts from the 2011 European Association for Vision and Eye Research Conference.
   Google Scholar
• Novagali Pharma Press Release, Trial Results phase II, September 2011. [cited 2018 July 25]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=255107
   Google Scholar
• Goh Y, Nakajim M, Azuma I, Hayashi O: Effects of prostaglandin D2 and its analogues on intraocular pressure in rabbits. Jpn J Ophthalmol. 1988;32:471–480.
   PubMed Web of Science ®Google Scholar
• Goh Y, Nakajim M. Azuma I: prostaglandin D2 reduces intraocular pressure. Br J Ophthalmol. 1988;72:461–464.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Goh Y, Azuma HO: Effects of prostaglandinD2 and its analogue, BW245C on intraocular pressure in humans. Graefes Arch Clin Exp Opthalmol. 1991;229:411–413.
   PubMed Web of Science ®Google Scholar
• Crawford KS, Kaufman PL, Hubbard WC, et al. The DP-receptor agonist SQ27986 raises but does not lower intraocular pressure in ocular normotensive monkeys. J Glaucoma. 1992;1:94–99.
   Google Scholar
• Hellberg MR, McLaughlin MA, Sharif NA, et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598,a DP prostaglandin receptor agonist. Surv Ophthalmol. 2002;47:S13–S33.
   PubMed Web of Science ®Google Scholar
• Torris CB, Zhan GL, Feilmeier MR, et al. Effects of a prostaglandin DP receptor agonist, AL-6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma. J Ocul Pharmacol Ther. 2006;22:86–92.
   PubMed Web of Science ®Google Scholar
• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090.
   PubMed Web of Science ®Google Scholar
• Shaikh Y, Yu F, Coleman AL. Burden of undetected and untreated glaucoma in the United States. Am J Ophthalmol. 2014;158(6):1121–9.e1.
   PubMed Web of Science ®Google Scholar
• Topouzis F, Coleman AL, Harris A, et al. Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study. Am J Ophthalmol. 2008;145(2):327–335.
   PubMed Web of Science ®Google Scholar
• Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016 Jan;123(1):129–140.
   PubMed Web of Science ®Google Scholar
• Ussa F, Fernandez I, Brion M, et al. Association between SNPs of metalloproteinases and prostaglandin F2α receptor genes and latanoprost response in open-angle glaucoma. Ophthalmology. 2015 May;122(5):1040–1048.
   PubMed Web of Science ®Google Scholar
• Herndon LW, Asrani SG, Williams GH, et al. Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost. Arch Ophthalmol. 2002 Jun;120(6):847–849.
   PubMedGoogle Scholar
• Kaufman PL. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opin Pharmacother. 2017 Mar;18(4):433–444.
   PubMed Web of Science ®Google Scholar